

Hikma Joins 50th World Economic Forum Annual Meeting in Davos, Switzerland

London, 23 January 2020 - Hikma Pharmaceuticals PLC (Hikma Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P), the multinational pharmaceutical company, has taken part in the 50th World Economic Forum (WEF) Annual Meeting, which was held under the theme 'Stakeholders for a Cohesive and Sustainable World' between 21-24 January 2020, in Davos, Switzerland.

The Annual Meeting convened 3,000 participants from around the globe to examine stakeholder capitalism; assist governments and international institutions in monitoring progress towards the Paris Agreement and the United Nations Sustainable Development Goals (UN SDG); and facilitate discussions on technology and trade governance. Throughout the four-day event, business, government and civil society leaders debated pressing global issues, with a focus on six key areas: Ecology, economy, technology, society, geopolitics and industry.

A longstanding WEF Health Industry Partner, Hikma joined other pioneers and policy-makers from the health industry, including international pharmaceutical companies, major health centres and hospitals, and top research and development centres and universities, to assess ways to improve the state of healthcare worldwide. Hikma reaffirmed its commitment to facilitating access to medications to patients worldwide, including in areas of political and economic unrest - particularly across the MENA region. In addition, Hikma continues to support and align its CSR strategy with the UN SDG's.

Representing Hikma at the Meeting, Executive Vice Chairman and President of MENA, Mazen Darwazah, participated in a private dinner session entitled 'The Middle East in the Fourth Industrial Revolution' where he led a group discussion about how to remain competitive in a fragile and fragmented region. The session participants representing regional government officials and senior leaders from the private sector, exchanged views on the impact of the Fourth Industrial Revolution on economic growth, innovation and the future of the MENA region in light of global shifts in technology, related challenges and opportunities, and efforts required to remain competitive. In addition to taking part in several global health and healthcare policy related sessions, Hikma, as a founding member of the Partnering Against Corruption Initiative (PACI) - the foremost CEO-led anti-corruption initiative - attended the PACI Vanguard meeting, which tackled pressing regional matters on industry anti-corruption practices in order to rebuild and foster trust in business.

Commenting on Hikma's participation in the 50th WEF Annual Meeting in Davos 2020, Mazen Darwazah said, "We are proud to have participated in this global Meeting as a long-standing partner. WEF in Davos is an important platform for us to meet with key health industry stakeholders and world leaders to discuss pressing global issues. As we start a new decade, it was enlightening this year, in particular, to hear different perspectives from the region about the challenges and opportunities the Fourth Industrial Revolution presents to different industries."

He added, "By working together, sharing industry knowledge and best practices, we can help shape a future presenting more opportunities for sustainable economic growth and regional stability."

- ENDS -

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for,



and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

Enquiries

Hikma Pharmaceuticals PLC

Dana Alhusseini
Communication Manager

+962 6 580 2900
Dalhusseini@hikma.com